Physician profile
Page Smith
NPI 1740301134
$1,655.80
in general payments reported to CMS, 2019-2025
32 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $297 · 2021: $146 · 2022: $270 · 2023: $423 · 2024: $407.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $830.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $829.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $209.98 | 2020 | |
| Novo Nordisk INC | $171.97 | 2019-2024 | Ozempic, Rybelsus |
| Lilly USA, LLC | $122.69 | 2023-2024 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $113.06 | 2023-2024 | Breztri, Farxiga |
| Teva Pharmaceuticals USA, INC. | $96.64 | 2023 | Austedo, Ajovy |
| Amgen INC. | $90.05 | 2019-2024 | Otezla, Repatha |
| Sumitomo Pharma America, INC. | $81.74 | 2023-2024 | Gemtesa |
| Abbvie INC. | $77.71 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $63.68 | 2022-2024 | |
| Glaxosmithkline, LLC. | $52.92 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Abbott Laboratories | $50.41 | 2023-2024 | Freestyle Libre 3 |
| Horizon Therapeutics Plc | $49.91 | 2019-2020 | |
| Astellas Pharma US INC | $42.65 | 2019-2023 | Myrbetriq |
| Allergan, INC. | $39.82 | 2020 | |
| Exact Sciences Corporation | $35.33 | 2023-2024 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $33.03 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.92 | 2024 | |
| Pfizer INC. | $30.06 | 2023-2024 | |
| Sanofi Pasteur INC. | $27.84 | 2019-2023 | |
| Edwards Lifesciences Corporation | $24.18 | 2023 | Sapien 3 Ultra Resilia |
| Merck Sharp & Dohme LLC | $23.37 | 2019-2022 | |
| Smith+Nephew, INC. | $22.80 | 2021-2022 | |
| Eisai INC. | $21.88 | 2023 | |
| Ucb, INC. | $19.95 | 2021 | |
| Sunovion Pharmaceuticals INC. | $19.33 | 2021 | |
| Janssen Pharmaceuticals, INC | $18.94 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $16.70 | 2022 | |
| Xeris Pharmaceuticals, INC. | $16.44 | 2021 | |
| Ge Healthcare | $15.44 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.57 | 2022 | |
| Genentech USA, INC. | $12.01 | 2019 | |
| Valeritas, INC. | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Page Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.